2.63
price up icon3.95%   0.10
pre-market  Vorhandelsmarkt:  2.69   0.06   +2.28%
loading
Schlusskurs vom Vortag:
$2.53
Offen:
$2.53
24-Stunden-Volumen:
5.43M
Relative Volume:
1.43
Marktkapitalisierung:
$564.56M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-3.0419
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
+4.78%
1M Leistung:
+6.91%
6M Leistung:
+71.90%
1J Leistung:
+20.64%
1-Tages-Spanne:
Value
$2.34
$2.67
1-Wochen-Bereich:
Value
$2.34
$2.70
52-Wochen-Spanne:
Value
$1.05
$3.31

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Firmenname
Taysha Gene Therapies Inc
Name
Telefon
(214) 612-0000
Name
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Name
Mitarbeiter
73
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
TSHA's Discussions on Twitter

Vergleichen Sie TSHA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
2.63 656.44M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-11 Eingeleitet BofA Securities Buy
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-04-09 Eingeleitet Piper Sandler Overweight
2023-02-01 Herabstufung Jefferies Buy → Hold
2023-01-27 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-09 Herabstufung Goldman Buy → Neutral
2022-03-09 Eingeleitet Robert W. Baird Outperform
2022-03-01 Eingeleitet Wells Fargo Overweight
2022-02-18 Eingeleitet SMBC Nikko Outperform
2021-12-16 Eingeleitet Guggenheim Buy
2021-07-16 Eingeleitet Needham Buy
2021-06-24 Eingeleitet Truist Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-06-09 Eingeleitet Wedbush Outperform
2021-06-08 Eingeleitet JMP Securities Mkt Outperform
2021-05-19 Eingeleitet Cantor Fitzgerald Overweight
2021-05-11 Fortgesetzt Jefferies Buy
2021-02-24 Eingeleitet William Blair Outperform
2021-01-05 Eingeleitet Oppenheimer Outperform
2020-10-19 Eingeleitet Chardan Capital Markets Buy
2020-10-19 Eingeleitet Goldman Buy
2020-10-19 Eingeleitet Jefferies Buy
2020-10-19 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten

pulisher
02:44 AM

What drives Taysha Gene Therapies Inc. stock priceOutstanding capital appreciation - Autocar Professional

02:44 AM
pulisher
01:24 AM

What analysts say about Taysha Gene Therapies Inc. stockTremendous return rates - Autocar Professional

01:24 AM
pulisher
Jul 22, 2025

Is Taysha Gene Therapies Inc. a good long term investmentHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Taysha Gene Therapies Inc. Stock Analysis and ForecastStrong return on assets - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Jul 16, 2025
pulisher
Jul 15, 2025

Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Taysha Gene Therapies Inc. stock performs during market volatilityFree Popular Stock Recommendations - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Coverage Initiated at Bank of America - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Biotech Bargains: Finding Gold in the Healthcare Sell-Off - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Taysha Gene's 5.9% Surge: A Deep Dive into the Unexplained Rally - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News - GuruFocus

Jul 11, 2025
pulisher
Jul 10, 2025

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN

Jul 10, 2025
pulisher
Jul 08, 2025

Goldman Sachs Group Inc's Strategic Acquisition in Taysha Gene Therapies Inc - GuruFocus

Jul 08, 2025
pulisher
Jul 03, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 03, 2025
pulisher
Jul 01, 2025

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock - Nasdaq

Jul 01, 2025
pulisher
Jul 01, 2025

Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Taysha Gene Therapies (TSHA) Receives Buy Rating from Needham | TSHA Stock News - GuruFocus

Jul 01, 2025
pulisher
Jun 30, 2025

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data - MSN

Jun 30, 2025
pulisher
Jun 25, 2025

Rhumbline Advisers Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 25, 2025
pulisher
Jun 24, 2025

Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT - Yahoo Finance

Jun 24, 2025
pulisher
Jun 22, 2025

Taysha Gene Therapies, Inc.(NasdaqGS:TSHA) added to S&P Biotechnology Select Industry Index - MarketScreener

Jun 22, 2025
pulisher
Jun 21, 2025

Taysha Gene Therapies (TSHA) Gets a Buy from Wells Fargo - The Globe and Mail

Jun 21, 2025
pulisher
Jun 14, 2025

Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia

Jun 14, 2025
pulisher
Jun 13, 2025

Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | TSHA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 06, 2025

Signify Bio’s $15M round advances in situ protein therapeutics - BioWorld MedTech

Jun 06, 2025
pulisher
Jun 06, 2025

Kalkine: Taysha Gene Therapies Grants Equity Awards to New Joiners – A Closer Look at FTSE 350 Companies' Global Peers - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

Jun 06, 2025

Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):